Ogundipe, Oyepeju
Mazidi, Mohsen
Chin, Ken Lee
Gor, Deval
McGovern, Andrew
Sahle, Berhe W.
Jermendy, György
Korhonen, Maarit Jaana
Appiah, Bernard
Ademi, Zanfina
De Bruin, Marie Louise
Liew, Danny
Ofori-Asenso, Richard http://orcid.org/0000-0002-6643-3269
Article History
Received: 16 June 2020
Accepted: 30 July 2020
First Online: 18 August 2020
Compliance with ethical standards
:
: DL reports past participation in advisory boards and/or receiving honoraria from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, and Shire for work unrelated to this study. RO and MLDB are employees of the Copenhagen Centre for Regulatory Sciences (CORS). CORS is a cross-faculty university anchored institution involving various public (Danish Medicines Agency, Copenhagen University) and private stakeholders (Novo Nordisk, Lundbeck, Ferring pharmaceuticals, LEO pharma) as well as patient organizations (Rare Diseases Denmark). The center is purely devoted to the scientific aspects of the regulatory field and with a patient-oriented focus, and the research is not company-specific product or directly company related and has received funding from Novo Nordisk, Ferring Pharmaceuticals, LEO pharma and Lundbeck for projects not related to this study. AM reports research funding from Eli Lilly, AstraZeneca, Boehringer Ingelheim, and Pfizer for work unrelated to this study. All others declare no relevant conflicts of interest.
: This article does not contain any studies with human or animal performed by any authors.
: Informed consent is not required.